A recent review of studies has reaffirmed that taking Tylenol during pregnancy does not elevate the risk of autism, ADHD, or intellectual disabilities. This finding challenges previous claims made by former President Donald Trump, who advised pregnant women against using the painkiller. The review, published on October 13, 2023, in The Lancet Obstetrics, Gynecology & Women’s Health, assessed 43 studies and concluded that the most rigorous research provides strong evidence against any connection between the widely used medication, known as paracetamol outside the United States, and these developmental disorders.
Dr. Asma Khalil, the lead author of the study and a fetal medicine specialist at St. George’s Hospital in London, emphasized the drug’s safety profile. “It remains the first line of treatment that we would recommend if a pregnant woman has pain or fever,” she stated. The review found that while some studies suggested a potential link between Tylenol usage during pregnancy and autism, the majority did not support this association.
Previous analyses, including a review published in BMJ last year and another in the Journal of the American Medical Association, have similarly indicated no clear connection between the use of Tylenol during pregnancy and the development of autism or ADHD in children. These findings underscore a significant body of evidence that contradicts claims suggesting otherwise.
In contrast, the White House has referenced studies that purportedly support a link between Tylenol and neurodevelopmental disorders. A paper cited on their website, published in BMC Environmental Health, reviewed 46 prior studies and found some support for a connection. However, health experts have criticized this interpretation, arguing that the association does not imply causation.
Dr. Andrea Baccarelli, the senior author of the aforementioned review, noted his background as an expert witness in a case related to acetaminophen and neurodevelopmental disorders, which has raised concerns about potential biases in the study’s conclusions. Despite these criticisms, he did not respond to inquiries regarding the findings.
Dr. Khalil pointed out that many studies indicating a link between Tylenol and autism fail to account for confounding factors. For instance, a pregnant woman may take Tylenol for a fever, which itself could increase the risk of autism. She also mentioned the risk of “recall bias,” where mothers might misremember their drug use after their child is diagnosed with autism.
The review highlights that when researchers utilize more rigorous study designs, such as sibling comparisons, the association between Tylenol and autism disappears. This suggests that genetics are the primary risk factor for autism, along with other factors like paternal age, preterm birth, and maternal health issues during pregnancy.
In a related commentary, a group of researchers from institutions including the London School of Hygiene and Tropical Medicine and Children’s Hospital Colorado warned against discouraging the use of acetaminophen during pregnancy. They emphasized that inadequate pain management could jeopardize both maternal and fetal health, as untreated fever and infection pose well-established risks to fetal development and survival.
Overall, the latest evidence strongly supports the continued use of Tylenol as a safe option for pain and fever relief in pregnant women, countering claims that have circulated in public discourse. The ongoing research in this area aims to provide clarity and reassurance for expectant mothers regarding medication use during pregnancy.
